NHS England

PocDoc partners with NHS Targeted Lung Health Programme in North East, leveraging new biomarker Coronary Artery Calcium, to identify patients at increased risk of cardiovascular disease

Retrieved on: 
Thursday, June 29, 2023

But these scans also identify the early stages of another common killer – coronary heart disease.

Key Points: 
  • But these scans also identify the early stages of another common killer – coronary heart disease.
  • Discovering these higher risk patients who have evidence of early disease, but are not already taking a statin, is an optimal way to maximise the health outcomes of the TLHC program.
  • The PocDoc pathway collects all the information needed for a cardiovascular risk assessment, including blood pressure and BMI.
  • We are proud to be partnering with PocDoc to demonstrate the North East's commitment to using innovation to save lives."

Responsible AI Institute Forms Inaugural Responsible Generative AI Consortium and Launches First in Series of Industry-Specific Testbeds to Operationalize AI Safety, Build Workforce Capacity

Retrieved on: 
Wednesday, June 28, 2023

Learnings from the Consortium will be unveiled at today’s Symposium on Responsible Generative AI in Healthcare hosted at St Edmund’s College, University of Cambridge.

Key Points: 
  • Learnings from the Consortium will be unveiled at today’s Symposium on Responsible Generative AI in Healthcare hosted at St Edmund’s College, University of Cambridge.
  • It will also facilitate cutting-edge research, sharing of case studies and executive education programs in responsible adoption of generative AI.
  • Policymakers can manage generative AI and its surrounding policies more efficiently to ensure the protection of consumers and promote the responsible use of AI.
  • We’ve joined forces with RAI Institute to be a part of the first-ever Responsible AI Consortium and look forward to ushering in a new era of responsible generative AI across industries worldwide,” said Seth Dobrin, CEO at Trustwise.

ADvantage Therapeutics Secures Approvals for Clinical Trial of AD04™ in Alzheimer’s Disease Treatment in Poland, Bulgaria, and Slovakia

Retrieved on: 
Tuesday, June 20, 2023

The 12-month study will evaluate various outcomes including hippocampal volume as a primary objective and biomarker endpoint.

Key Points: 
  • The 12-month study will evaluate various outcomes including hippocampal volume as a primary objective and biomarker endpoint.
  • The Company plans additional European study sites, incorporating additional countries such as France, Germany, and Austria.
  • Achim Schneeberger, M.D., chief medical officer of ADvantage Therapeutics, commented, “This represents an important milestone in the launch of our confirmatory trial.
  • For more information on ADvantage Therapeutics, Inc., please visit www.advantagetherapeutics.com

'Leeds 2023': can investment in culture improve a city's health? Yes, but more ambition is needed

Retrieved on: 
Wednesday, May 10, 2023

There is a growing interest in the value of arts and culture in supporting health and wellbeing.

Key Points: 
  • There is a growing interest in the value of arts and culture in supporting health and wellbeing.
  • For example, the government’s Know Your Neighbourhood Fund, aimed at tackling loneliness, has earmarked £5 million to expand arts, culture and heritage activities across 27 target areas.
  • At the Centre for Cultural Value, we have spent the past two years exploring research to learn about the impact of culture on health and wellbeing.
  • This has resulted in an apparent postcode lottery for what does and doesn’t get commissioned by the NHS.

Scaling understanding

    • One answer lies in developing a better understanding over a longer term.
    • Previous studies show that the creative and cultural sectors can be powerful drivers of innovation, job creation and economic growth.
    • However, alongside our partners at The Audience Agency, we will focus on drawing out arguably the more difficult-to-quantify social impacts.

Capturing complexity: the next steps

    • Capturing and conveying the nuanced value of culture in health and wellbeing is complex, but not impossible.
    • This partly means shifting away from short-term funding models, where small pots of money are available for time-limited projects.
    • They can also provide powerful moments of joy, connection and wonder – at a time when people need them most.

With 7 months still to go, Over 100 exhibitors confirmed for the UK's Largest EV Event

Retrieved on: 
Friday, May 5, 2023

London, UK, May 5, 2023 - (ACN Newswire) - The London EV Show is all set to be bigger and better than ever before, with the confirmation of over 100 exhibitors just a few months ahead of the event launch.

Key Points: 
  • London, UK, May 5, 2023 - (ACN Newswire) - The London EV Show is all set to be bigger and better than ever before, with the confirmation of over 100 exhibitors just a few months ahead of the event launch.
  • The show will also offer a unique platform for networking and collaboration, bringing together key players in the industry to share ideas, insights, and experiences.
  • "This year's event promises to be a fantastic showcase of the latest trends and disruptions in EVs and sustainable transport solutions.
  • Get ready for an electrified experience at the London EV Show

GROWING CRISIS IN NHS ALLERGY SERVICES PUTS LIVES AT RISK

Retrieved on: 
Tuesday, April 25, 2023

LONDON, April 25, 2023 /PRNewswire/ -- Allergy UK is today urging government to heed its call to introduce specialist allergy nurses and dietitians to GP services.

Key Points: 
  • LONDON, April 25, 2023 /PRNewswire/ -- Allergy UK is today urging government to heed its call to introduce specialist allergy nurses and dietitians to GP services.
  • The UK is one of the top three countries in the world with the highest incidence of allergy.
  • With allergy service provision still seemingly undefined by the majority of NHS England ICBs, Allergy UK is calling for each ICS in England to introduce an allergy nurse and dietitian at primary care level.
  • Its prevalence in society is growing and our healthcare system is inadequately addressing the issue of allergy because there isn't enough specialist allergy knowledge at a GP level.

Masimo Announces FDA Clearance of the Rad-G® with Temperature

Retrieved on: 
Tuesday, April 18, 2023

Masimo (NASDAQ: MASI) today announced that the Rad-G® with Temperature has received FDA 510(k) clearance.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that the Rad-G® with Temperature has received FDA 510(k) clearance.
  • With the addition of temperature measurements, Rad-G is more versatile than ever, streamlining the assessment of multiple key vital signs.
  • With this FDA clearance, Rad-G with Temperature can now be deployed across the U.S., in addition to many other parts of the world, helping support clinicians in almost any care scenario.”
    The infrared thermometry offered by Rad-G with Temperature provides a host of benefits.
  • In addition to temperature measurements and Masimo SET® oxygen saturation (SpO2) and pulse rate (PR), the same SpO2 sensor can be used to monitor respiration rate from the plethysmograph, with RRp.

MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease

Retrieved on: 
Wednesday, April 5, 2023

ILAP was established in 2021 to reduce the time to market for innovative medicines in the United Kingdom.

Key Points: 
  • ILAP was established in 2021 to reduce the time to market for innovative medicines in the United Kingdom.
  • In addition, patients are also considered key partners and the patient voice is integrated at every development stage.
  • “We are delighted that MHRA has recognized the potential of AD04™ at same time we are launching our confirmatory trial,” said Jeffrey Madden, chief executive officer of ADvantage.
  • We hope this AD04 trial with ILAP designation will bring us one step closer,” he concluded.

Dental Fluoride Treatment Market Report 2023: Rising Prevalence Of Dental Caries Bolsters Demand - ResearchAndMarkets.com

Retrieved on: 
Friday, March 31, 2023

The "Dental Fluoride Treatment Market Size, Share & Trends Analysis Report By Product (Varnish, Toothpaste, Mouth Rinse, Gel, Supplements, Others), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dental Fluoride Treatment Market Size, Share & Trends Analysis Report By Product (Varnish, Toothpaste, Mouth Rinse, Gel, Supplements, Others), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global dental fluoride treatment market size is expected to reach USD 20,545.6 million by 2030, and expand at a CAGR of 3.9% from 2023 to 2030.
  • The market is owing to the increasing prevalence of dental caries coupled with growing awareness about oral health.
  • These factors would certainly boost the demand for dental fluoride treatment products.